Our experience suggests that further research with alemtuzumab is attractive in islet
transplantation. Therefore, in this study we propose to combine alemtuzumab induction
pre-transplant, with tacrolimus and mycophenolate mofetil maintenance immunosuppression
post-transplant. In the critical early phase post transplant, we anticipate that this regimen
will prove to be more effective in control of autoimmunity or rejection events, and have a
more desirable side-effect profile, than previously tested combinations of induction and
immunosuppressive agents.